NuPathe Inc. (PATH) reported a fourth-quarter net loss applicable to common shareholders of $19.1 million or $1.15 per share, compared to a net loss of $5.6 million or $0.38 per share in the fourth quarter of 2011. The latest-quarter result included a $13.25 million non-cash charge for a deemed dividend related to the preferred stock that we issued in October 2012.
Excluding this non-cash charge, the net loss for the fourth quarter of 2012 would have been $5.9 million.
Research and development expenses were $1.1 million in the fourth quarter of 2012, compared with $3.2 million in the fourth quarter of 2011. The fourth quarter 2012 decrease was largely attributable to reduced spending on clinical and manufacturing related expenses for ZECUITY.
Operating expenses for the quarter declined to $3.67 million from $5.11 million in the year ago quarter.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.33 per share for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.